UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):  January 29, 2007

 

BRUKER BIOSCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

 

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (978) 663-3660

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Section 2 — Financial Information

Item 2.02.         Results of Operations and Financial Condition

On January 29, 2007, Bruker BioSciences Corporation issued a press release announcing selected preliminary financial results for the three and twelve months ended December 31, 2006.  A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

2

---

 

Section 9 — Financial Statements and Exhibits

Item 9.01.         Financial Statements and Exhibits.

(d)  Exhibits

 

 

Exhibit 99.1 attached hereto shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and shall be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

3

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BRUKER BIOSCIENCES CORPORATION (Registrant)
Date: January 29, 2007		By:		/s/ Frank H. Laukien
				Frank H. Laukien, Ph.D. Chief Executive Officer and President

 

4

---

 

Exhibit Index

Exhibit Number		Exhibit Name		Location
99.1		Press release dated January 29, 2007.		Filed herewith

 

 

5